Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta

January 26, 2017
Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 2016, Flexion Therapeutics CEO Mike Clayman is hoping for priority review of the filing, in addition to fast track status. Zilretta is an extended release formulation of the triamcinolone acetonide. Steroid injection is a common treatment, but pain relief wanes after two to four weeks. Competing against generic steroids, which cost only USD 10–20 per dose, presents a big commercial challenge however. In an interview at Biotech Showcase, Clayman explains the rationale for pricing a long-acting steroid at USD 500 per dose and the company's commercial strategy.
Previous Video
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML

Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the t...

Next Video
Luc André Granier – Founder, CEO and Medical Director, Advicenne Pharma SA
Luc André Granier – Founder, CEO and Medical Director, Advicenne Pharma SA